Compare Hormel Foods Corp (HRL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs ResMed Inc. — how do they compare? Hormel Foods Corp trades at $24.41 (market cap $13.37B), while ResMed Inc. trades at $225.88 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 2.4× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.81%). Which is the better fit depends on your goals.
| HRL | RMD | |
|---|---|---|
Market Cap | $13.37B | $32.61B |
Sector | Consumer Staples | Health |
52-Week High | $29.25 | $293.73 |
52-Week Low | $19.74 | $182.82 |
Enterprise Value | $15.37B | $31.97B |
Dividend Yield | 4.81% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $24.23, down 1.92% over 24 hours, amid a bearish technical signal. The stock shows consistent earnings beats with Q1 2026 EPS of $0.40 surpassing the $0.3544 estimate. Revenue for 2025 was $12.11B, though net income margin compressed to 3.82%. Recent corporate developments include the appointment of John Ghingo as CEO and the sale of its CERATTI business in Brazil.
HRL presents a mixed outlook with a defensive profile as a consumer staple, supported by a 4.6% dividend yield. However, margin pressures and a bearish technical trend pose near-term risks. The consensus price target of $26.33 implies modest upside, but investor sentiment remains cautious given high hold ratings.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
